Oncotype DX Breast Cancer Assay

Known as: Oncotype DX 
A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
PURPOSE Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the… (More)
Is this relevant?
2015
2015
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score
Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
This retrospective study evaluated the impact of intermediate Recurrence Score(®) results on adjuvant treatment decisions in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2014
2014
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre
INTRODUCTION The use of chemotherapy in node-negative, (O)Estrogen Receptor (ER)-positive breast cancer has changed significantly… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2011
2011
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by…
PURPOSE The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?
Oncotype DXTM is an RT-PCR-based assay used to predict chemotherapy benefit in patients with estrogen receptor (ER) positive… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2010
2010
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort
The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
Novel genetic profiling tests of breast cancer tissue have been shown to be prognostic for overall survival and predictive of… (More)
  • table 1
  • figure 1
Is this relevant?
2006
2006
A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
We now recognize that not all breast cancers are the same. Different characteristics in gene expression profiles result in… (More)
Is this relevant?